GW Pharmaceuticals Announces Mixed Results

GW Pharma has released mixed results for the year, with sales rising and profits decreasing, but the company continues to demonstrate potential in their R&D pipeline with inspiring data for a mid-stage, cannaboid-based diabetes drug. The organisation saw their sales for the year ending September 30, 2012, increase by £3.5 million to reach £33.1 million,

Continue Reading

Bayer Withdraws Schiff Bidding Interest

Bayer have declared that they are not going to follow plans to purchase American vitamins company, Schiff Nutrition International, four days after their $1.20 billion offer was beaten by Reckitt Benckiser. Roughly three weeks ago, Bayer announced a bid of $34 per share to acquire Schiff, but Reckitt since revealed an offer of $42.00 per

Continue Reading

NHS hospital prescribing costs remain high

New and expensive treatments are continuing to drive up NHS prescribing costs in England’s hospitals. This is according to a new IMS Health report, commissioned by the NHS, which found that hospital prescribing costs in England increased by 6.9% in 2011, far outstripping the 1.9% growth seen in primary care. The rate of increase is

Continue Reading

Novo Nordisk Q3 Net Profit Grows 26%

Novo Nordisk revealed more healthy sales figures yesterday for their third quarter results, aided by solid sales of their diabetes drug, Victoza, and its modern insulins. The company announced an 18% growth in sales to a total of 57.1 billion Danish kroner ($9.9 billion).  Operating profit increased 34% to 21.9 billion kroner.  Their net profit

Continue Reading

Novo Nordisk Q3 Net Profit Grows 26%

Novo Nordisk revealed more healthy sales figures yesterday for their third quarter results, aided by solid sales of their diabetes drug, Victoza, and its modern insulins. The company announced an 18% growth in sales to a total of 57.1 billion Danish kroner ($9.9 billion).  Operating profit increased 34% to 21.9 billion kroner.  Their net profit

Continue Reading

AstraZeneca Announce 15% Sales Drop

AstraZeneca have announced a dip of 15% for their Q3 sales, mainly as a result of the loss of exclusivity on several key brands, and costs relating to the disposal of their former Astra Tech and Aptium Oncology units. The Anglo-Swedish organisation’s revenue fell to $6.8 million in comparison to quarter 3 in 2011.  Antipsychotic

Continue Reading